Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Therapeutics Report 2016 - Pipeline Review of 10 Companies & 12 Molecules - Research and Markets

Research and Markets
Posted on: 03 Oct 16

Research and Markets has announced the addition of the "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline Review, H2 2016" report to their offering.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Anca vasculitis is a type of autoimmune swelling caused by autoantibodies. Symptoms include fatigue, weight loss, fever, shortness of breath, joint pain, bloody sputum, bloody nose

nasal discharge, nasal ulcerations and hearing problems or hearing loss.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) pipeline therapeutics constitutes close to 12 molecules. which approximately 12 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 3, 1, 1, 1, 4 and 1 respectively.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Overview
  3. Therapeutics Development
  4. Pipeline Products for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Overview
  5. Pipeline Products for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Comparative Analysis
  6. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Therapeutics under Development by Companies
  7. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Therapeutics under Investigation by Universities/Institutes
  8. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Products under Development by Companies
  13. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Products under Investigation by Universities/Institutes
  14. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - Companies Involved in Therapeutics Development
  • Bionovis SA
  • Bristol-Myers Squibb Company
  • ChemoCentryx, Inc.
  • Coherus BioSciences, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • KPI Therapeutics, Inc.
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • The International Biotechnology Center (IBC) Generium

For more information about this report visit http://www.researchandmarkets.com/research/26mq62/antineutrophil

View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006241/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.